Leukemia Clinical Trials

A listing of Leukemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 573 clinical trials
PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT (PTCyRuxo)

This is multicenter investigator-initiated randomized open-label phase II clinical trial to compare prophylaxis of graft versus host disease treated with tacrolimus and mycophenolate mofetil versus ruxolitinib after post-transplant cyclophosphamide. In total 128 patients will be included in the study. After inclusion into the study and performing of transplantation patients will …

flow cytometry
graft versus host disease
remission
cyclophosphamide
blast cells
  • 0 views
  • 19 Apr, 2022
  • 2 locations
CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies (CLIC-01)

) cells for participants with relapsed/refractory CD19 positive (CD19+) Acute Lymphoblastic Leukemia (ALL) and non-Hodgkin's Lymphoma (NHL). The Initial Stage of the study (n=20 participants) will focus

diffuse large b-cell lymphoma
cancer
leukemia
lymphoma
large b-cell lymphoma
  • 12 views
  • 18 Apr, 2022
  • 2 locations
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

This phase II trial studies how well enasidenib and azacitidine work in treating patients with IDH2 gene mutation and acute myeloid leukemia that has come back (recurrent) or does not respond to

IDH2
cancer
myelomonocytic leukemia
enasidenib
leukemia
  • 13 views
  • 28 May, 2022
  • 1 location
  • 0 views
  • 16 Jun, 2022
  • 1 location
Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence

The objective of this study is to improve medication, symptom, and disease management of patients with hematological malignancies and multiple chronic conditions (2 or more conditions in addition to cancer) through care coordination between pharmacists working in oncology practices and those working in primary care or community practices (Pharmacists Coordinated …

  • 0 views
  • 17 Jun, 2022
  • 1 location
A Study of ASTX030 (Cedazuridine in Combination With Azacitidine) in MDS, CMML, or AML

Study ASTX030-01 is designed to move efficiently from Phase 1 to Phase 3. Phase 1 consists of an open-label Dose Escalation Stage (Stage A) using multiple cohorts at escalating dose levels of oral cedazuridine and azacitidine (only one study drug will be escalated at a time) followed by a Dose …

direct bilirubin
graft versus host disease
bone marrow procedure
conjugated bilirubin
chronic myelomonocytic leukemia
  • 0 views
  • 30 Apr, 2022
  • 4 locations
ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

-mutated acute myeloid leukemia that is newly diagnosed, has come back (relapsed) or does not respond to treatment (refractory) or high-risk myelodysplastic syndrome. Chemotherapy drugs, such as ASTX727

cancer
venetoclax
leukemia
serum bilirubin level
hemolysis
  • 0 views
  • 09 May, 2022
  • 1 location
Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation

This phase II trial studies how well olaparib works in treating patients with acute myeloid leukemia that has come back (relapsed) or does not respond to treatment (refractory), or

hysterectomy
cancer
leukemia
blast cells
myeloid leukemia
  • 0 views
  • 19 Jun, 2022
  • 4 locations
Ruxolitinib and Venetoclax in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

This phase I trial studies the side effects and best dose of ruxolitinib when given together with venetoclax in treating patients with acute myeloid leukemia that has come back (relapsed) or has

ruxolitinib
refractory acute myeloid leukemia (aml)
myeloid leukemia
cancer
ejection fraction
  • 5 views
  • 11 Apr, 2022
  • 2 locations
Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study

This phase II trial studies how well daratumumab and ibrutinib work in treating patients with chronic lymphocytic leukemia that has come back (relapsed) or has not responded to previous

flow cytometry
monoclonal antibodies
direct bilirubin
monoclonal protein
cancer
  • 0 views
  • 14 Apr, 2022
  • 1 location